Under the agreement, Systagenix will co-market EpiFix, MiMedx’s proprietary biologic implant processed from amniotic tissue. Systagenix will conduct the first phase of the EpiFix global launch throughout the United States, followed by other countries.
MiMedx will continue selling EpiFix through existing distributor channels.
More Articles on Orthopedic Devices:
US Implantable Medical Devices Demand to Increase 7.7% Annually Through 2015
Exactech’s Deferred Prosecution Agreement Expires
BioMimetic Reports 2011 Revenue
